US 12,349,967 B2
Methods, apparatuses, and systems for the treatment of pulmonary disorders
Jonathan Reuben Waldstreicher, West Orange, NJ (US); William Sanford Krimsky, Forest Hil, MD (US); Denise Marie Zarins, Saratoga, CA (US); Robert J. Beetel, III, Sunnyvale, CA (US); Paul Brian Friedrichs, Belmont, CA (US); Kevin James Taylor, San Mateo, CA (US); Roman Turovskiy, San Francisco, CA (US); and Gary L. Long, Cincinnati, OH (US)
Assigned to Galvanize Therapeutics, Inc., Redwood City, CA (US)
Filed by Galvanize Therapeutics, Inc., Redwood City, CA (US)
Filed on Nov. 6, 2024, as Appl. No. 18/939,459.
Application 18/939,459 is a continuation of application No. 17/824,720, filed on May 25, 2022.
Application 17/824,720 is a continuation of application No. 16/227,796, filed on Dec. 20, 2018, granted, now 11,369,433, issued on Jun. 28, 2022.
Application 16/227,796 is a continuation of application No. PCT/US2017/039527, filed on Jun. 27, 2017.
Claims priority of provisional application 62/489,753, filed on Apr. 25, 2017.
Claims priority of provisional application 62/355,164, filed on Jun. 27, 2016.
Prior Publication US 2025/0064510 A1, Feb. 27, 2025
Int. Cl. A61B 18/18 (2006.01); A61B 18/12 (2006.01); A61B 18/14 (2006.01); A61N 1/06 (2006.01); A61N 1/32 (2006.01); A61B 18/00 (2006.01)
CPC A61B 18/1492 (2013.01) [A61B 18/1206 (2013.01); A61N 1/06 (2013.01); A61N 1/327 (2013.01); A61B 2018/0016 (2013.01); A61B 2018/0022 (2013.01); A61B 2018/00267 (2013.01); A61B 2018/00541 (2013.01); A61B 2018/00577 (2013.01); A61B 2018/00642 (2013.01); A61B 2018/00648 (2013.01); A61B 2018/00678 (2013.01); A61B 2018/00702 (2013.01); A61B 2018/00791 (2013.01); A61B 2018/00839 (2013.01); A61B 2018/00875 (2013.01); A61B 2018/1435 (2013.01); A61B 2018/1467 (2013.01)] 25 Claims
OG exemplary drawing
 
1. A system for treating a target tissue of a patient, comprising:
at least one energy delivery body positionable near the target tissue;
a dispersive electrode positionable upon the patient at a location that causes the at least one energy delivery body to function in a monopolar fashion; and
a generator comprising at least one energy delivery algorithm configured to provide pulsed high voltage energy having a voltage of 500 to 5000 volts and packets of pulses that cause disruption of at least intracellular organelles of the target tissue, thereby leading to cell death by non-thermal mechanisms.